Search…

    Saved articles

    You have not yet added any article to your bookmarks.

    Browse articles

    GDPR Compliance

    We use cookies to ensure you get the best experience on our website. By continuing to use our site, you accept our use of cookies, Privacy Policies, and Terms of Service.

    Pfizer is halting development of its experimental weight-loss pill, as the booming obesity drug market remains out of reach for the drug giant

    1 week ago

    12

    0

    Danuglipron was the latest drug investors were hinging hope on to enter the obesity market.
    Click here to Read more
    Prev Article
    The U.S. continued to generate jobs at a brisk pace in February, offering reassurances that the labor market has remained strong since President Trump took office
    Next Article
    Five years after the pandemic’s start, long-Covid patients young and old continue to struggle with cognitive difficulties

    Related Health Updates:

    Comments (0)

      Leave a Comment